GlassScriptPhysician profile
Radwan Asaad
NPI 1578761037
$3,083.86
in general payments reported to CMS, 2019-2025
36 companies · $587 in 2025
The $587 reported for 2025 was more than what 83% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $153 · 2021: $278 · 2022: $595 · 2023: $586 · 2024: $707 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.58 |
| Education | $175.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $521.41 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $410.58 | 2019-2024 | Lo Loestrin Fe, Orilissa |
| Aspira Women'S Health INC | $316.99 | 2022-2024 | Ova1 |
| Hologic Sales and Service, LLC | $276.12 | 2019-2025 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $166.51 | 2023-2025 | Myfembree, Gemtesa |
| Gynesonics, INC. | $164.38 | 2021-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Caldera Medical, INC | $158.78 | 2024 | Desara |
| Mayne Pharma Commercial LLC | $147.19 | 2022-2025 | |
| Myovant Sciences INC. | $100.06 | 2021-2022 | |
| Sage Therapeutics, LLC | $87.02 | 2025 | Zurzuvae |
| Organon LLC | $81.10 | 2023-2025 | Nexplanon |
| Exeltis, USA INC. | $66.58 | 2024-2025 | Slynd |
| Pfizer INC. | $61.21 | 2023-2024 | |
| Coloplast Corp | $49.76 | 2019-2023 | Altis |
| Daiichi Sankyo INC. | $44.42 | 2024-2025 | Injectafer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $42.56 | 2019-2025 | Paragard T 380a |
| Exact Sciences Corporation | $37.05 | 2024-2025 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $35.88 | 2020-2022 | |
| Applied Medical Resources Corporation | $32.19 | 2024 | |
| Bluewind Medical | $22.97 | 2025 | Revi |
| Baxter Healthcare | $21.88 | 2025 | Tisseel |
| Lupin INC. | $20.89 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $20.74 | 2023 | Vivjoa |
| Millicent US INC | $20.58 | 2025 | Femlyv |
| Medtronic, INC. | $19.84 | 2023 | Truclear |
| Smith+Nephew, INC. | $19.66 | 2023 | Grafix Pl |
| Shield Therapeutics INC | $19.62 | 2024 | |
| Amgen INC. | $17.33 | 2019 | |
| Ascend Therapeutics US, LLC | $17.00 | 2023 | |
| Medicem INC. | $16.53 | 2020 | |
| Dexcom, INC. | $14.76 | 2023 | Dexcom G6 Transmitter |
| Vertical Pharmaceuticals, LLC | $14.47 | 2020 | |
| Evofem Biosciences, INC. | $13.76 | 2022 | |
| Avion Pharmaceuticals | $12.90 | 2023 | Balcoltra |
| Therapeuticsmd, INC. | $11.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radwan Asaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.